文献速递神经肿瘤

皮质非强化肿瘤浸润:IDH突变型胶质瘤的预测性影像生物标志物

Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma.
PubMed 文献 · J Neurosurg · 2025-04-04

研究评估皮质非强化肿瘤浸润(CONTIN)征作为IDH突变型弥漫性胶质瘤预测性影像标志物的价值。训练集来自北京天坛医院526例,验证集来自UCSF PDGM数据集501例。CONTIN征在IDH突变型胶质瘤中总体患病率分别为90.1%和85.4%,在强化胶质瘤中敏感性显著优于T2-FLAIR不匹配征。

要点

  • CONTIN征评估者间一致性几乎完美(κ=0.812)。
  • 强化胶质瘤中CONTIN征敏感性在BTH队列从14.8%升至92.2%,UCSF队列从23.3%升至81.4%。
  • CONTIN征特异性在BTH队列为82.8%,UCSF队列为87.4%,阴性预测值分别为94.6%和97.6%。

核心结论

  • CONTIN征是识别弥漫性胶质瘤IDH突变状态的稳健影像生物标志物,尤其适用于强化胶质瘤。
  • 术前了解IDH突变状态可加强患者咨询并辅助治疗决策。

研究设计与样本

  • 影像数据来自北京天坛医院2019年1月至2021年12月弥漫性胶质瘤(2-4级)患者(训练集,n=526)和UCSF术前弥漫性胶质瘤MRI数据集(UCSF PDGM;验证集,n=501)。
  • 两名独立评估者评估CONTIN征及其他影像学特征以制定诊断策略。

主要发现

  • CONTIN征评估者间一致性几乎完美(κ=0.812)。
  • BTH队列中IDH突变型胶质瘤CONTIN征总体患病率为90.1%,强化胶质瘤为92.2%(106/115),非强化胶质瘤为88.9%(168/189)。
  • UCSF PDGM队列中总体患病率为85.4%,强化胶质瘤为81.4%,非强化胶质瘤为88.3%。
  • 强化胶质瘤中CONTIN征敏感性较T2-FLAIR不匹配(T2FMM)征显著提高,BTH队列从14.8%升至92.2%,UCSF PDGM队列从23.3%升至81.4%。
  • CONTIN征特异性在BTH队列为82.8%,UCSF PDGM队列为87.4%;阴性预测值在BTH队列为94.6%,UCSF PDGM队列为97.6%。

关键数值与推荐

  • 整合CONTIN征与T2FMM、对比强化、诊断时年龄及其他特征,建立了可靠的IDH突变型胶质瘤诊断方案。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the cortical nonenhancing tumor infiltration (CONTIN) sign as a predictive imaging biomarker for IDH-mutant gliomas, including diffuse gliomas with and without contrast enhancement. METHODS: Imaging data were collected from patients with diffuse gliomas (grades 2-4) at Beijing Tiantan Hospital (BTH) from January 2019 to December 2021 (training set, n = 526) and from the University of California, San Francisco, preoperative diffuse glioma MRI dataset (UCSF PDGM; validation set, n = 501). Two independent reviewers assessed the CONTIN sign and other radiological features to develop a diagnostic strategy. RESULTS: Interrater agreement for the CONTIN sign was almost perfect (κ = 0.812). In the BTH cohort, the prevalence of the CONTIN sign in IDH-mutant gliomas was 90.1% overall, with a rate of 92.2% (106/115) in contrast-enhancing gliomas and 88.9% (168/189) in nonenhancing gliomas. In the UCSF PDGM cohort, the overall prevalence was 85.4%, with 81.4% in contrast-enhancing gliomas and 88.3% in nonenhancing gliomas. In contrast-enhancing gliomas, the CONTIN sign significantly improved sensitivity compared with the T2-FLAIR mismatch (T2FMM) sign, with an increase from 14.8% to 92.2% in the BTH cohort and from 23.3% to 81.4% in the UCSF PDGM cohort. Additionally, the CONTIN sign had a high specificity (82.8% in the BTH cohort, 87.4% in the UCSF PDGM cohort) and negative predictive value (94.6% in the BTH cohort, 97.6% in the UCSF PDGM cohort). By integrating the CONTIN sign with T2FMM, contrast enhancement, age at diagnosis, and other features, a reliable diagnostic protocol for IDH-mutant gliomas was established. CONCLUSIONS: The CONTIN sign was a robust imaging biomarker for identifying IDH mutation status in diffuse glioma, particularly for those with contrast enhancement. Preoperative knowledge of IDH mutation status can enhance patient counseling and inform treatment decision-making.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang X, Jiang H, Li M, et al. Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma. J Neurosurg. 2025. PMID: 40184682. doi:10.3171/2024.11.JNS242017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。